Cited by 539Atrial Fibrillation Management and OutcomesECG Monitoring and AnalysisNon-Invasive Vital Sign Monitoring

Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial

Open access
Steinhubl, Steven R., Waalen, Jill, Edwards, Alison M., Ariniello, Lauren M., Mehta, Rajesh R., Ebner, Gail S., Carter, Chureen, Baca-Motes, Katie +3 more·2018·JAMA

Abstract

Importance: Opportunistic screening for atrial fibrillation (AF) is recommended, and improved methods of early identification could allow for the initiation of appropriate therapies to prevent the adverse health outcomes associated with AF. Objective: To determine the effect of a self-applied wearable electrocardiogram (ECG) patch in detecting AF and the clinical consequences associated with such a detection strategy. Design, Setting, and Participants: A direct-to-participant randomized clinical trial and prospective matched observational cohort study were conducted among members of a large national health plan. Recruitment began November 17, 2015, and was completed on October 4, 2016, and 1-year claims-based follow-up concluded in January 2018. For the clinical trial, 2659 individuals were randomized to active home-based monitoring to start immediately or delayed by 4 months. For the observational study, 2 deidentified age-, sex- and CHA2DS2-VASc-matched controls were selected for each actively monitored individual. Interventions: The actively monitored cohort wore a self-applied continuous ECG monitoring patch at home during routine activities for up to 4 weeks, initiated either immediately after enrolling (n = 1364) or delayed for 4 months after enrollment (n = 1291). Main Outcomes and Measures: The primary end point was the incidence of a new diagnosis of AF at 4 months among those randomized to immediate monitoring vs delayed monitoring. A secondary end point was new AF diagnosis at 1 year in the combined actively monitored groups vs matched observational controls. Other outcomes included new prescriptions for anticoagulants and health care utilization (outpatient cardiology visits, primary care visits, or AF-related emergency department visits and hospitalizations) at 1 year. Results: The randomized groups included 2659 participants (mean [SD] age, 72.4 [7.3] years; 38.6% women), of whom 1738 (65.4%) completed active monitoring. The observational study comprised 5214 (mean [SD] age, 73.7 [7.0] years; 40.5% women; median CHA2DS2-VASc score, 3.0), including 1738 actively monitored individuals from the randomized trial and 3476 matched controls. In the randomized study, new AF was identified by 4 months in 3.9% (53/1366) of the immediate group vs 0.9% (12/1293) in the delayed group (absolute difference, 3.0% [95% CI, 1.8%-4.1%]). At 1 year, AF was newly diagnosed in 109 monitored (6.7 per 100 person-years) and 81 unmonitored (2.6 per 100 person-years; difference, 4.1 [95% CI, 3.9-4.2]) individuals. Active monitoring was associated with increased initiation of anticoagulants (5.7 vs 3.7 per 100 person-years; difference, 2.0 [95% CI, 1.9-2.2]), outpatient cardiology visits (33.5 vs 26.0 per 100 person-years; difference, 7.5 [95% CI, 7.2-7.9), and primary care visits (83.5 vs 82.6 per 100 person-years; difference, 0.9 [95% CI, 0.4-1.5]). There was no difference in AF-related emergency department visits and hospitalizations (1.3 vs 1.4 per 100 person-years; difference, 0.1 [95% CI, -0.1 to 0]). Conclusions and Relevance: Among individuals at high risk for AF, immediate monitoring with a home-based wearable ECG sensor patch, compared with delayed monitoring, resulted in a higher rate of AF diagnosis after 4 months. Monitored individuals, compared with nonmonitored controls, had higher rates of AF diagnosis, greater initiation of anticoagulants, but also increased health care resource utilization at 1 year. Trial Registration: ClinicalTrials.gov Identifier: NCT02506244.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2018.8102

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • One pioneering trial used a 'band-aid' patch sensor for detecting atrial fibrillation; the sensor was mailed to participants who were enrolled remotely, without the use of any clinical sites, and set the foundation for digitized clinical trials.

    “One pioneering trial used a 'band-aid' patch sensor for detecting atrial fibrillation; the sensor was mailed to participants who were enrolled remotely, without the use of any clinical sites, and set the foundation for digitized clinical trials 37 .”

    From Multimodal biomedical AI (2022) · cites this paper as [37]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Atrial fibrillation screening via ECG patches in selected high-risk individuals is feasible and clinically valuable.

    “AF screening via ECG patches in selected high-risk individuals is feasible and clinically valuable50”
  • In the mSToPS study, ECG monitoring led to a higher rate of new AF diagnosis at 4 months and 1 year and was associated with increased initiation of anticoagulation therapy and outpatient cardiology and primary care visits in patients without previously known AF.

    “The study showed that ECG monitoring led to a higher rate of new AF diagnosis at 4 months and 1 year and was associated with the increased initiation of anticoagulation therapy and outpatient cardiology and primary care visits in patients without previously known AF50.”
  • iRhythm's single-use Zio patch monitors electrical pulses from the heart for 14 days.

    “For example, iRhythm's single-use Zio patch monitors electrical pulses from the heart for 14 days, and is more effective than intermittent hospital check-ups at detecting abnormal rhythms 4 .”

    From Skin sensors are the future of health care (2019) · cites this paper as [4]

  • The Zio patch is more effective than intermittent hospital check-ups at detecting abnormal rhythms.

    “For example, iRhythm's single-use Zio patch monitors electrical pulses from the heart for 14 days, and is more effective than intermittent hospital check-ups at detecting abnormal rhythms 4 .”

    From Skin sensors are the future of health care (2019) · cites this paper as [4]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 51 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

  1. Goldstein LB, Bushnell CD, Adams RJ, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke. Stroke. 2011; 42(2):517-584.
  2. Proietti M, Mairesse GH, Goethals P, et al; Belgian Heart Rhythm Week Investigators. A population screening programme for atrial fibrillation. Europace. 2016;18(12):1779-1786.
  3. Lowres N, Krass I, Neubeck L, et al. Atrial fibrillation screening in pharmacies using an iPhone ECG. Int J Clin Pharm. 2015;37(6):1111-1120.
  4. Muse ED, Wineinger NE, Spencer EG, et al. Validation of a genetic risk score for atrial fibrillation. PLoS Med. 2018;15(3):e1002525.
  5. Mahajan R, Perera T, Elliott AD, et al. Subclinical device-detected atrial fibrillation and stroke risk. Eur Heart J. 2018;39(16):1407-1415.
  6. Chen LY, Chung MK, Allen LA, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity. Circulation. 2018;137(20):e623-e644.

Cited by

Sorted by citations

Authors
Steinhubl, S. R., Waalen, J., Edwards, A. M., Ariniello, L. M., Mehta, R. R., Ebner, G. S., Carter, C., Baca-Motes, K., Felicione, E., Sarich, T., & Topol, E. J.
Affiliations
  • Scripps Translational Science Institute, La Jolla, California
  • Healthagen Outcomes, Chicago, Illinois
  • Janssen Scientific Affairs (United States) (US)
Corresponding author
Steinhubl, Steven R.
Venue
JAMA
Published
2018-07-10
Volume
320
Issue
2
Pages
146
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2869528658
Cited by
539
References
51
Citations by year
2026: 65 · 2025: 70 · 2024: 58 · 2023: 56 · 2022: 72 · 2021: 79 · 2020: 68 · 2019: 58 · 2018: 13
FWCI
41.17
Type
journal article
Language
en
Open access
Locations
  • JAMA (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR001114)
  • National Center for Advancing Translational Sciences
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › ECG Monitoring and Analysis
  • Physical Sciences › Engineering › Biomedical Engineering › Non-Invasive Vital Sign Monitoring
Keywords
atrial fibrillation, opportunistic screening, undiagnosed atrial fibrillation, anticoagulant prescription, health care utilization, CHA2DS2-VASc score, stroke prevention, older adults, health insurance beneficiaries, emergency department visits, hospitalization, primary care visits, cost-effectiveness
MeSH terms
Wearable Electronic Devices, Aged, Anticoagulants, Atrial Fibrillation, Female, Health Resources, Humans, Male, Mass Screening, Middle Aged, Risk Factors, Cohort Studies, Electrocardiography, Ambulatory, Comorbidity, Incidence, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review